A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Public ClinicalTrials.gov record NCT05147805. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.
Study identification
- NCT ID
- NCT05147805
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 102 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 24, 2022 (Actual)
- Primary completion
- Mar 27, 2025 (Actual)
- Completion
- Mar 27, 2025 (Actual)
- Last update posted
- Mar 30, 2026
2022 – 2025
United States locations
- U.S. sites
- 21
- U.S. states
- 10
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USA025 | Phoenix | Arizona | 85006 | — |
| USA022 | Scottsdale | Arizona | 85258 | — |
| USA021 | Tucson | Arizona | 85724 | — |
| USA023 | Sacramento | California | 95817 | — |
| USA002 | West Hollywood | California | 90048 | — |
| USA008 | Gainesville | Florida | 32610 | — |
| USA005 | Jacksonville | Florida | 32224 | — |
| USA007 | Orlando | Florida | 32803 | — |
| USA011 | Tampa | Florida | 33601 | — |
| USA010 | Winter Park | Florida | 32792-3800 | — |
| USA009 | Atlanta | Georgia | 30309 | — |
| USA006 | Chicago | Illinois | 60611 | — |
| USA001 | Chicago | Illinois | 60612 | — |
| USA013 | Indianapolis | Indiana | 46260 | — |
| USA014 | Iowa City | Iowa | 52242 | — |
| USA003 | Kansas City | Kansas | 66160 | — |
| USA102 | New York | New York | 10021 | — |
| USA017 | New York | New York | 10032-1559 | — |
| USA016 | Dallas | Texas | 75246 | — |
| USA012 | Denison | Texas | 75020 | — |
| USA018 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05147805, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 30, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05147805 live on ClinicalTrials.gov.